Trial Profile
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 15 Feb 2023 Results (n=21) assessing efficacy (5-year clinical outcomes) and safety of nivolumab in resectable non-small cell lung cancer, published in the Clinical Cancer Research.
- 08 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Oct 2027.
- 08 Feb 2023 Status changed from recruiting to active, no longer recruiting.